Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2000
08/17/2000WO2000047040A1 Growth medium for human corneal endothelial cells
08/17/2000WO2000038654B1 Synthetic and therapeutic methods for the alpha and beta domains of metallothionein
08/17/2000WO2000034317A3 Method for reducing immunogenicity of proteins
08/17/2000WO2000032629A3 Antiviral peptides
08/17/2000WO2000030675A3 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
08/17/2000WO2000030590A3 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
08/17/2000WO2000027340A3 USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF
08/17/2000WO2000026374A3 Adipose specific protein
08/17/2000WO2000024766A3 New transcription factor of mhc class ii genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
08/17/2000WO2000021574A3 Site-directed dual pegylation of proteins
08/17/2000WO2000018912A3 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
08/17/2000WO2000017356A3 Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
08/17/2000WO2000015784A3 Human and murine g-protein-coupled edg6 receptor (endothelial differentiation gene) and use of same
08/17/2000WO2000015773A3 Inhibition of oncogene transcription by synthetic polyamides
08/17/2000WO2000015665A3 A method of producing a functional immunoglobulin superfamily protein
08/17/2000WO2000012711A3 Human membrane channel proteins
08/17/2000WO2000012076A9 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
08/17/2000WO2000011157A9 Dysferlin, a gene mutated in distal myopathy and limb girdle muscular dystrophy
08/17/2000WO2000009109A3 Pipecolic acid derivatives for vision and memory disorders
08/17/2000WO1999064594A3 Genes and gene expression products that are differentially regulated in prostate cancer
08/17/2000WO1998015626A3 Mutant ciita molecule and uses thereof
08/17/2000DE19956568A1 Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens Method and medicament for the inhibition of expression of a given gene
08/17/2000DE19948867A1 Tumor necrosis factor alpha binding peptide comprises 4-9 amino acids
08/17/2000DE19906108A1 Schutz von Zellen im Zusammenhang mit einer Behandlung mit chemischen Agenzien Protecting cells in connection with a treatment with chemical agents
08/17/2000DE19906096A1 Protein mit einem Heparin-bindenden Epitop Protein having a heparin-binding epitope
08/17/2000DE19905501A1 Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels A method of producing a recombinant adeno-associated virus, as well as suitable means to this end use for the preparation of a medicament
08/17/2000DE19904650A1 cDNA-Sequenz eines Interaktors FANCIP1 des Fanconi-Anämie-Proteins der Komplementationsgruppe A cDNA sequence of an interactor FANCIP1 of the Fanconi anemia complementation group A protein
08/17/2000CA2367575A1 Stimulating neutrophil function to treat inflammatory bowel disease
08/17/2000CA2362592A1 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
08/17/2000CA2362574A1 Antiangiogenic drugs
08/17/2000CA2362560A1 Controlling protein levels in eucaryotic organisms
08/17/2000CA2362525A1 Cyclic peptides and aids vaccines
08/17/2000CA2362523A1 Nitroreductase enzymes
08/17/2000CA2362464A1 A synthetic peptide disturbing intracellular signaling
08/17/2000CA2362373A1 Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor
08/17/2000CA2362368A1 Method for altering undesirable immune responses to polypeptides
08/17/2000CA2362295A1 Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
08/17/2000CA2362258A1 Peptides inhibiting vascular endothelial cell migration
08/17/2000CA2362109A1 Novel antisense inhibition of rad51
08/17/2000CA2361919A1 Lactam inhibitors of fxa and method
08/17/2000CA2361335A1 Inhibiting formation of atherosclerotic lesions
08/17/2000CA2361334A1 Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
08/17/2000CA2361293A1 33 human secreted proteins
08/17/2000CA2361034A1 Proteins related to neuronal regeneration and uses thereof
08/17/2000CA2360324A1 Peptide yy (pyy) for inducing glucose responsiveness in pancreatic islets
08/17/2000CA2360319A1 Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts
08/17/2000CA2360292A1 Immunogenic compositions for use as vaccines
08/17/2000CA2360131A1 Methods of inactivating pathogens using broad-spectrum pulsed light
08/17/2000CA2360103A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
08/17/2000CA2359926A1 Antagonists of hmg1 for treating inflammatory conditions
08/17/2000CA2359799A1 Neisseria meningitidis serogroup b antigen
08/17/2000CA2359785A1 .beta.-secretase enzyme compositions and methods
08/17/2000CA2359748A1 Method of producing a recombinant adeno-associated virus, suitable means for producing the same and use thereof for producing a medicament
08/17/2000CA2359747A1 Human uncoupling proteins and polynucleotides encoding the same
08/17/2000CA2297441A1 Fusion proteins comprising carriers that can induce a dual immune response
08/16/2000EP1028137A2 Polymeric matrices and their uses in pharmaceutical compositions
08/16/2000EP1028126A1 Depsipeptide derivatives bearing piperazinone rings
08/16/2000EP1027896A1 Broadly reactive opsonic antibodies that react with common staphyloccoccal antigens
08/16/2000EP1027894A2 Pharmaceutical preparation for the treatment of inflammatory processes
08/16/2000EP1027893A2 Alginate containing medicament and implant for treating fibrosis
08/16/2000EP1027834A1 Food composition comprising L-arginine
08/16/2000EP1027455A2 Methods and compositions for targeting dna metabolic processes using aminoglycoside derivatives
08/16/2000EP1027444A1 Reagents and methods useful for detecting diseases of the breast
08/16/2000EP1027443A2 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
08/16/2000EP1027440A1 Inhibitor protein of the wnt signal pathway
08/16/2000EP1027439A2 Multivalent antigen-binding proteins
08/16/2000EP1027438A2 Novel cytokine receptors
08/16/2000EP1027437A1 Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
08/16/2000EP1027436A1 Viral encoded semaphorin protein receptor dna and polypeptides
08/16/2000EP1027435A2 Nucleic acid molecule encoding a (poly)peptide co-segregating in mutated form with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (apeced)
08/16/2000EP1027432A2 RIBOZYMES TARGETED TO IL-15 mRNA
08/16/2000EP1027431A2 April- a novel protein with growth effects
08/16/2000EP1027430A1 64 human secreted proteins
08/16/2000EP1027429A1 Jnk3 modulators and methods of use
08/16/2000EP1027424A1 Regulators of ucp3 gene expression
08/16/2000EP1027374A1 Nucleotide sequences
08/16/2000EP1027373A1 Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression
08/16/2000EP1027371A1 Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma
08/16/2000EP1027370A2 A method for mapping the active sites bound by enzymes that covalently modify substrate molecules
08/16/2000EP1027076A2 Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
08/16/2000EP1027075A1 Gene therapy for stimulation of angiogenesis
08/16/2000EP1027071A2 Encapsulated immunomodulators useful as vaccine adjuvants
08/16/2000EP1027069A1 Compositions and methods for treating lysosomal storage disease
08/16/2000EP1027068A1 Oromucosal cytokine compositions and uses thereof
08/16/2000EP1027067A1 Use of substances having oxytocin activity for preparation of medicaments for the treatment of affective pain syndromes
08/16/2000EP1027066A1 Soluble mhc complexes and methods of use thereof
08/16/2000EP1027065A1 Method for destroying retinal pigment epithelial cells
08/16/2000EP1027063A1 Mannose receptor bearing cell line and antigen composition
08/16/2000EP1027059A2 Enhancement of morphogen activity
08/16/2000EP1027056A1 Alpha-ketoamide multicatalytic protease inhibitors
08/16/2000EP1027053A1 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
08/16/2000EP1027036A2 Taste masked formulations
08/16/2000EP1027027A2 Therapeutic method
08/16/2000EP1027014A1 Implantable system with drug-eluting cells for on-demand local drug delivery
08/16/2000EP0759302B1 Remedy for rheumatoid arthritis
08/16/2000EP0753015B1 Monoclonal antibodies recognizing tie-receptor and their use
08/16/2000EP0726076B1 Method of stabilizing protein c or activated protein c and stabilized composition
08/16/2000EP0668914B1 Crystallization of m-csf
08/16/2000EP0509080B1 Inhibitors and substrates of thrombin
08/16/2000EP0463126B1 Methods of enhancing wound healing and tissue repair